Multiple Organ Failure Associated with SARS-CoV-2 Infection in a Child with Down Syndrome: Is Trisomy 21 Associated with an Unfavourable Clinical Course?

Introduction: Down syndrome (DS) is one of the most frequent genomic disorders around the globe (∼1:700 births). During the COVID-19 pandemic, it has been recognized that children with DS are patients with a greater risk of presenting SARS-CoV-2 infection-related poor outcomes. Nonetheless, a few cases with DS and SARS-CoV-2 infection have been reported.

[B-type brain natriuretic peptide as marker of hemodynamic overload of the patent ductus arteriosus in the preterm infant].

Introducción: El ecocardiograma es el método de referencia para el diagnóstico del conducto arterioso permeable (CAP) hemodinámicamente significativo (CAP-hs) del recién nacido prematuro (RNP). El péptido natriurético tipo B (BNP) puede ser útil en el diagnóstico y el manejo del CAP-hs. Objetivo: Evaluar la utilidad del BNP como marcador de sobrecarga hemodinámica del conducto arterioso permeable en el RNP con edad gestacional < 32 semanas o peso < 1500 gramos, e identificar el mejor punto de corte para los valores de BNP que mejor prediga un CAP con repercusión hemodinámica que requiera tratamiento farmacológico o quirúrgico.

[Percutaneous closure of patent ductus arteriosus using the Amplatzer vascular Plug II].

Unlabelled: The Amplatzer vascular II Plug (AVPII) is a self- expanding occluder device, indicated for arterial and venous occlusion in the peripheral circulation.

Objective: To describe our initial clinical experience with the AVP II, in the percutaneous closure of small patent ductus arteriosus.

Method: We retrospectively analyzed seven patients who underwent percutaneous closure of patent ductus arteriosus.

[Transcatheter closure of patent ductus arteriosus using the Amplatzer duct occluder in children: initial and one-year results].

Objective: Percutaneous closure of patent ductus arteriosus (PDA) is a well established technique. Our objective was to determine the safety and efficacy of the Amplatzer occluder for the treatment of PDA in children.

Methods: From November 2005 to June 2007 we reviewed the clinical records of 39 patients (23 girls and 16 boys), with a mean age of 19.

Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under 1 year of age.

Introduction And Objectives: Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age.

Methods: The patients' mean age was 8.

Transcatheter closure of patent ductus arteriosus using the amplatzer duct occluder in infants under one year of age.

Introduction And Objectives: Percutaneous closure of patent ductus arteriosus (PDA) is a well-established technique. We evaluated the usefulness of the Amplatzer duct occluder for the percutaneous closure of patent ductus arteriosus in 29 children under 1 year of age.

Methods: The patients' mean age was 8.